Liu Dan, Ju Chenhui, Han Chao, Shi Rui, Chen Xuehui, Duan Demin, Yan Jinghua, Yan Xiyun
CAS Engineering Laboratory for Nanozyme, Institute of Biophysics, Chinese Academic of Science, Beijing, 100101, China.
CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Biosens Bioelectron. 2021 Feb 1;173:112817. doi: 10.1016/j.bios.2020.112817. Epub 2020 Nov 13.
COVID-19 has evolved into a global pandemic. Early and rapid detection is crucial to control of the SARS-CoV-2 transmission. While representing the gold standard for early diagnosis, nucleic acid tests for SARS-CoV-2 are often complicated and time-consuming. Serological rapid antibody tests are characterized by high rates of false-negative diagnoses, especially during early infection. Here, we developed a novel nanozyme-based chemiluminescence paper assay for rapid and sensitive detection of SARS-CoV-2 spike antigen, which integrates nanozyme and enzymatic chemiluminescence immunoassay with the lateral flow strip. The core of our paper test is a robust Co-Fe@hemin-peroxidase nanozyme that catalyzes chemiluminescence comparable with natural peroxidase HRP and thus amplifies immune reaction signal. The detection limit for recombinant spike antigen of SARS-CoV-2 was 0.1 ng/mL, with a linear range of 0.2-100 ng/mL. Moreover, the sensitivity of test for pseudovirus could reach 360 TCID/mL, which was comparable with ELISA method. The strip recognized SARS-CoV-2 antigen specifically, and there was no cross reaction with other coronaviruses or influenza A subtypes. This testing can be completed within 16 min, much shorter compared to the usual 1-2 h required for currently used nucleic acid tests. Furthermore, signal detection is feasible using the camera of a standard smartphone. Ingredients for nanozyme synthesis are simple and readily available, considerably lowering the overall cost. In conclusion, our paper test provides a high-sensitive point-of-care testing (POCT) approach for SARS-CoV-2 antigen detection, which should greatly facilitate early screening of SARS-CoV-2 infections, and considerably lower the financial burden on national healthcare resources.
新型冠状病毒肺炎已演变成一场全球大流行疾病。早期快速检测对于控制严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播至关重要。虽然核酸检测是SARS-CoV-2早期诊断的金标准,但往往复杂且耗时。血清学快速抗体检测的特点是假阴性诊断率高,尤其是在早期感染期间。在此,我们开发了一种基于纳米酶的新型化学发光试纸检测法,用于快速灵敏地检测SARS-CoV-2刺突抗原,该方法将纳米酶和酶促化学发光免疫分析与侧流试纸条相结合。我们试纸检测的核心是一种强大的钴-铁@血红素过氧化物酶纳米酶,它催化的化学发光与天然过氧化物酶辣根过氧化物酶(HRP)相当,从而放大免疫反应信号。SARS-CoV-2重组刺突抗原的检测限为0.1 ng/mL,线性范围为0.2-100 ng/mL。此外,对假病毒检测的灵敏度可达360 TCID/mL,与酶联免疫吸附测定(ELISA)方法相当。该试纸条能特异性识别SARS-CoV-2抗原,与其他冠状病毒或甲型流感亚型无交叉反应。该检测可在16分钟内完成,与目前常用核酸检测所需的通常1-2小时相比要短得多。此外,使用标准智能手机的摄像头即可进行信号检测。纳米酶合成的成分简单且容易获得,大大降低了总成本。总之,我们的试纸检测为SARS-CoV-2抗原检测提供了一种高灵敏度的即时检测(POCT)方法,这将极大地促进SARS-CoV-2感染的早期筛查,并大大减轻国家医疗资源的经济负担。